Within these genes, through proteomic study, BAG3 may affect AD by influencing the interpretation of Aβ and tau protein, and patients with AD have much lower levels of SEZ6 in their cerebrospinal fluid than those without dementia (Khoonsari et al., 2016; Gonzalez-Rodriguez et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.